2025 Japan Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 Japan Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in ALS treatment in Japan include Mitsubishi Tanabe Pharma Corporation, Biogen, Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma developed Radicava (edaravone), approved in Japan since 2015, with recent advancements such as Radicava ORS oral suspension boosting sales and ongoing clinical research. Biogen leads with gene-targeted therapies, notably QALSODY (amylyx), targeting SOD1-ALS mutations, marking a pioneering step in Japan's ALS precision medicine. Eisai launched Rozebalamin (mecobalamin) in 2024, an injection drug shown to slow ALS progression based on the Japan Early-stage Trial (JETALS). Otsuka Pharmaceutical is acknowledged among key ALS market leaders contributing to innovation and research in Japan.
These companies shape Japan’s ALS market through approved drugs, gene therapy innovations, and strong clinical trial efforts. Mitsubishi Tanabe’s edaravone represents a foundational ALS treatment with evolving formulations, while Biogen’s gene-based approach meets precision medicine needs. Eisai’s recent product offers a novel treatment path with clinical backing from Japanese trials. Otsuka supports ALS advancement through research partnerships and drug development. Together, they drive Japan’s position as a critical hub for ALS treatment innovation and commercial activity.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in ALS treatment in Japan include Mitsubishi Tanabe Pharma Corporation, Biogen, Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma developed Radicava (edaravone), approved in Japan since 2015, with recent advancements such as Radicava ORS oral suspension boosting sales and ongoing clinical research. Biogen leads with gene-targeted therapies, notably QALSODY (amylyx), targeting SOD1-ALS mutations, marking a pioneering step in Japan's ALS precision medicine. Eisai launched Rozebalamin (mecobalamin) in 2024, an injection drug shown to slow ALS progression based on the Japan Early-stage Trial (JETALS). Otsuka Pharmaceutical is acknowledged among key ALS market leaders contributing to innovation and research in Japan.
These companies shape Japan’s ALS market through approved drugs, gene therapy innovations, and strong clinical trial efforts. Mitsubishi Tanabe’s edaravone represents a foundational ALS treatment with evolving formulations, while Biogen’s gene-based approach meets precision medicine needs. Eisai’s recent product offers a novel treatment path with clinical backing from Japanese trials. Otsuka supports ALS advancement through research partnerships and drug development. Together, they drive Japan’s position as a critical hub for ALS treatment innovation and commercial activity.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
